← Eichor
Condition: Cd123 Acute Myeloid Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cd123 Acute Myeloid Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
Phase 1 · 11 location(s) · AvenCell Europe GmbH · NCT05949125A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leuk
Phase 2 · 32 location(s) · Stemline Therapeutics, Inc. · NCT06456463Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT03222674Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Phase 1/Phase 2 · 1 location(s) · Stanford University · NCT06561152Off-the-shelf CD123 CAR-NK for R/R AML
EARLY_Phase 1 · 1 location(s) · Peking University People's Hospital · NCT06201247Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07523555Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Phase 1 · 5 location(s) · Vincerx Pharma, Inc. · NCT06034275CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial
EARLY_Phase 1 · 1 location(s) · Institute of Hematology and Blood Transfusion, Czech Republi · NCT06765876Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hemato
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06498973CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Phase 1 · 2 location(s) · St. Jude Children's Research Hospital · NCT04318678Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN
Phase 1 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06690827CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Stephan Grupp MD PhD · NCT07464951Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dend
Phase 1/Phase 2 · 1 location(s) · Chongqing Precision Biotech Co., Ltd · NCT06006403Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
Phase 1/Phase 2 · 1 location(s) · Xuzhou Medical University · NCT06125652CD123-CD16-NK Cells Immunotherapy for AML
Phase 1 · 1 location(s) · Chunji Gao · NCT06835140Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT06420063Multiple CAR-T Cell Therapy Targeting AML
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT04010877Universal CAR-T Cells Targeting AML
Phase 1 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT05995041
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.